Jordan Elizabeth Lake MD

Infectious Disease•Houston, TX

Associate Professor, Medicine, University of Texas Health Science Center at Houston

Join to View Full Profile

2015 Thomas StHouston, TX 77009
Phone+1 713-500-6759
Fax+1 832-487-2011

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Infectious Disease, 2007 - 2011
Baylor College of MedicineResidency, Internal Medicine, 2004 - 2007
Baylor College of MedicineClass of 2004

Certifications & Licensure

CA State Medical License 2007 - Present
TX State Medical License 2018 - 2025
American Board of Internal Medicine Infectious Disease

Clinical Trials

HIV and Fat Accumulation Start of enrollment: 2010 May 01
Completed
Phase 2
Vitamin D in HIV-Infected Patients on HAART Start of enrollment: 2010 Oct 01
Completed
Not Applicable
A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease Start of enrollment: 2012 Aug 01
Completed
Phase 2
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Start of enrollment: 2013 Feb 01
Terminated
Effects of Vitamin D Insufficiency in Man Start of enrollment: 2010 Aug 01
Completed
Not Applicable
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study) Start of enrollment: 2014 Jan 01
Completed
Phase 2
A Pilot Study to Examine Efficacy of Peer Mentoring in Promoting Medication Adherence Among People Living With HIV/AIDS Start of enrollment: 2013 Sep 01
Unknown status
Not Applicable
(mo)BETTA Trial in Transwomen for Optimization of ART Start of enrollment: 2018 Jun 06
Terminated
Phase 4
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) Start of enrollment: 2021 Feb 19
COMPLETED
PHASE2
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007) Start of enrollment: 2020 Apr 24
Completed
Phase 3
Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) Start of enrollment: 2020 Apr 15
Active, not recruiting
Phase 2
Ramipril for the Treatment of COVID-19 Start of enrollment: 2020 May 11
Completed
Phase 2
Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance Start of enrollment: 2020 Oct 22
Completed
Join now to see all

Publications & Presentations

PubMed

1 citations
Short and Long-term Body Weight Change Following the Switch to or the Addition of Integrase Inhibitors in Persons With HIV Differs by Sex.
Cecile D Lahiri, C Christina Mehta, Qian Yang, Tsungirirai Maramba, Joffi Musonge-Effoe
Clinical Infectious Diseases. 2025-03-17
4 citations
Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.
Grace L Ditzenberger, Jordan E Lake, Douglas W Kitch, Amy Kantor, Raja Muthupillai
Clinical Infectious Diseases. 2025-02-24
Centering autonomy and choice to support oral PrEP utilization among people who inject drugs: qualitative lessons from HPTN 094 INTEGRA.
Amaya Perez-Brumer, Rose Schmidt, Rebecca Kennedy, Jordan E Lake, Yolanda R Villarreal
Addiction Science & Clinical Practice. 2024-12-18

Journal Articles

To T or Not to T: Differences in Testosterone Use and Discontinuation by HIV Serostatus Among Men Who Have Sex with Men*
T T Brown, J E Lake, W S Post, A Dobs, HIV Medicine

Grant Support

Metabolic impact of FGF-21 in adipose tissue and liver of PLWHUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON2020–2025

Jordan Elizabeth Lake MD

Dr. Lake is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Grant Support

Viewing the full profile is available to verified healthcare professionals only.